Epidemiological Characters of Renal Malignancies in Midland Region of Libya; Single Center Experience (National cancer institute Misrata Libya).
Abstract
Introduction: Renal malignancy accounts for 5% and 3% of all adult malignancies in men and women respectively. Renal cell carcinoma (RCC) forms 85% of all primary renal neoplasms. Some of the reported risk factors for RCC include gender, age and other associated factors such as hypertension by chronic use of diuretics, diabetes, urinary tract infections.
Aims: The aim of this study is to clarify epidemiological and clinicopathological features of malignant renal tumors in central region of Libya.
Methods: From January 2014 to December 2019, 57 patients at National Cancer Institute of Misurata proved histopathologically with renal malignancy are included in this study. Related variables such as patients’ demographic features, clinical presentation, size of tumor and laterality, type of surgery, type of chemotherapies and metastatic status were collected from the medical records and pathology reports. All variables were analyzed using the software of “Statistical Package for the Social Sciences†(SPSS), version 20.
Results: In total, 57 patients were diagnosed with renal malignancy, 31 were females (54.5%) and 26 were males (45.6 %) and clear cell histopathological type form 68.4% of them. The most common presenting symptom was loin pain in 73.7 % of patients followed by, abdominal mass in 47.4 %, while hematuria was seen in 38 % of patients and weight loss was reported by one fourth of patients. The distant metastases were seen in 47.4 % of patients. Regarding laterality, 56.1 % of patients had right kidney tumor and 43.9 % had left kidney tumor. Radical nephrectomy carried out in 53 % of patients, cytoreductive nephrectomy for 12 % of patients and 5 % of patients underwent partial nephrectomy . Conclusion: The incidence of such tumors in Libya has increased, and further cohort studies on risk factors, pathogenesis, and efficacy of minimally invasive surgery vs open surgery are required. Implications of immunochemical stains is critical for suspicious of new metachronous tumors affected by same hormonal receptors. Establishing or introducing screening service in Libya to help in early-stage detection. Importance of target therapy as part of neoadjuvant therapy to prove adequate free resection margin and metastasis cure.
References
2.Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018; 7:307.
3. Medina-Rico M, Ramos HL, Lobo M, Romo J, Prada JG. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J. 2018; 12(3):E154–E162.
Corresponding author: dr.sidoun.mohamed1982@gmail.com Vol. 7 (Jan., 2021)
4.Mohammadian M, Pakzad R, Towhidi F, Makhsosi BR, Ahmadi A, Salehiniya H. Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012. Clujul Med. 2017; 90(3):286– 293.
5. Shinder BM, Rhee K, Farrell D, et al. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol. 2017; 7:107. Published 2017 May 31.
6. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003 ;30(4):843–52.
7.Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, et al. Cytoreductive surgery prior to interleukin- 2-based therapy in patients with metastatic renal cell carcinoma. Urology 1993; 42(3):250–7
8. Krabbe, L. M., Bagrodia, A., Margulis, V., & Wood, C. G.. Surgical management of renal cell carcinoma. Seminars in interventional radiology 2014 ;31(1): 27–32.
9. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 2013 ;63(6):1107–14.
10. Shahait M, Mukherji D, El-Hout Y . Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand? Indian J Urol. 2015; 31(2):102–105.
11. Tatjana Antic, Jerome B. Taxy, Partial Nephrectomy for Renal Tumors: Lack of Correlation Between Margin Status and Local Recurrence, American Journal of Clinical Pathology 2015 ;143(5): 645–651.
12. Roos, F.C., Steffens, S., Junker, K. et al. Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma. BMC Cancer 2014; 14:372.
13. Ferlay J, et al. GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. [accessed on Aug 4, 2016]; International Agency for Research on Cancer Web site. 2016 Available online: http://globocan.iarc.fr.
14. Van Poppel H, Becker F, Cadeddu JA, Gill IS, et al. Treatment of localised renal cell carcinoma. Eur Urol. 2011;60 (4): 662-672.
15. Wong, M.C.S., Goggins, W.B., Yip, B.H.K. et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep 7, 15698 (2017).
16. Mufid El, Arduino V, Ivan R, Nadia E, Mohamed El and Massimo F. Cancer incidence in eastern Libya: The first report from the Benghazi Cancer Registry, 2003, Int. J. Cancer 2006 ;120:392–397.
17. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: A trend analysis. Eur Urol 2011; 59:135-41
18. Safaa M, Abdulla Y. malignant renal tumors in Iraq (clinical & epidemiological study), Thi-Qar Medical Journal (TQMJ) 2011; 5 (2) (117-126)
19. Sultan A, Ali A, Abdulmalik A, Raed A,Tarek M, Emad M . Kidney cancer in Saudi Arabia, Saudi Med J 2018; 39 (5): 459–463.
20. Ingimarsson JP, Sigurdsson MI, Hardarson S, et al. The impact of tumour size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: a population-based study [published correction appears in BMC Urol. 2015; 15:5]. BMC Urol. 2014; 14:72.
21. di Martino, S., De Luca, G., Grassi, L. et al. Renal cancer: new models and approach for personalizing therapy. J Exp Clin Cancer Res, 2018; 37 :217.
